Sun Pharma launches FluGuard® (Favipiravir) in India at Rs. 35 per tablet

Sun Pharmaceutical Industries Limited. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies) today announced that it has launched FluGuard® (Favipiravir 200 mg) at an economical price of Rs. 35 per tablet, for the treatment of mild to moderate cases of Covid-19 in India. Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease.

Commenting on the launch, Kirti Ganorkar, CEO of India Business, Sun Pharma said, "With over 50,000 Covid-19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals. We are launching FluGuard® at an economical price to make the drug accessible to more and more patients thereby reducing their financial burden. This is in line with our continuous efforts to support India's pandemic response."

The company will work closely with the government and medical community to ensure availability of FluGuard® to patients across the country. The stocks of FluGuard® will be available in the market from this week.

FluGuard® is the registered trade mark of Sun Pharma.

Shares of SUN PHARMACEUTICAL INDUSTRIES LTD. was last trading in BSE at Rs.528.5 as compared to the previous close of Rs. 519.8. The total number of shares traded during the day was 445809 in over 10099 trades.

The stock hit an intraday high of Rs. 532.15 and intraday low of 517.2. The net turnover during the day was Rs. 234142000.

Source : Equity Bulls

Keywords